Theralase Technologies Inc. V.TLT

I think they should keep the lights !

[Oden6570]

Roger DuMoulin-White, B.Sc., P.Eng., Pro.Dir., President and Chief Executive Officer of Theralase® stated, “The activation of Rutherrin® by Metformin is a game changer in the clinical use of Rutherrin®. By activating it, without light and/or radiation, this treatment can significantly be expanded to offering it on an out-patient basis or even an in-home treatment basis. Traditionally, Rutherrin®, is required to be activated by laser light and/or radiation, but now it is envisioned that Rutherrin® can be instilled in the body via IV drip followed by activation with Metformin, taken orally. This can be accomplished virtually anywhere, and if required, can be accompanied by hospital-based radiation treatments, if the disease state requires it. Based on the latest research, pending Good Laboratory Practices toxicology analysis of Rutherrin® and regulatory approval, Theralase® plans to commence practitioner-led and/or Theralase®-led, clinical studies in the destruction of various cancers. The clear advantage is that light and/or radiation equipment is no longer a prerequisite and the procedure can be completed outside of the hospital or expensive operating room, significantly lowering the cost of providing the treatment and the burden on elderly patients, with limited mobility. We look forward to commercializing this technology and its ease of delivery for the benefit of all patients stricken with this terrible disease.”
Theralase® Demonstrates Unique Ability to Activate Rutherrin® with Diabetes Drug – Theralase Technologies